NasdaqGM - Delayed Quote • USD
Rhythm Pharmaceuticals, Inc. (RYTM)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 6:29 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | -2.16 | -0.67 | -4.14 | -2.04 |
| Low Estimate | -2.41 | -0.8 | -4.95 | -3.84 |
| High Estimate | -0.59 | -0.59 | -2.19 | -0.79 |
| Year Ago EPS | -0.92 | -0.82 | -3.2 | -4.14 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | 27.02M | 31.57M | 133.03M | 207.54M |
| Low Estimate | 25.8M | 29.6M | 115.61M | 164.72M |
| High Estimate | 28M | 33.9M | 141M | 298.46M |
| Year Ago Sales | 11.47M | 19.22M | 77.43M | 133.03M |
| Sales Growth (year/est) | 135.60% | 64.20% | 71.80% | 56.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.9 | -0.79 | -0.74 | -0.7 |
| EPS Actual | -0.92 | -0.82 | -0.76 | -0.7 |
| Difference | -0.02 | -0.03 | -0.02 | 0 |
| Surprise % | -2.20% | -3.80% | -2.70% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -2.16 | -0.67 | -4.14 | -2.04 |
| 7 Days Ago | -2.16 | -0.67 | -4.12 | -2.03 |
| 30 Days Ago | -2.15 | -0.66 | -4.11 | -2.01 |
| 60 Days Ago | -0.7 | -0.64 | -2.53 | -1.38 |
| 90 Days Ago | -0.69 | -0.62 | -2.4 | -1.24 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 2 |
Growth Estimates
| CURRENCY IN USD | RYTM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -134.80% | -- | -- | 0.80% |
| Next Qtr. | 18.30% | -- | -- | 9.60% |
| Current Year | -29.40% | -- | -- | 4.50% |
| Next Year | 50.70% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -9.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Wells Fargo: Overweight to Overweight | 4/18/2024 |
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Reiterates | Needham: Buy to Buy | 2/22/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 1/26/2024 |
| Reiterates | Needham: Buy to Buy | 1/26/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 1/25/2024 |
Related Tickers
DYN Dyne Therapeutics, Inc.
23.65
-4.71%
PCVX Vaxcyte, Inc.
60.62
-2.90%
IGMS IGM Biosciences, Inc.
7.41
-8.86%
BPMC Blueprint Medicines Corporation
88.90
+0.59%
ACLX Arcellx, Inc.
54.50
+1.77%
PHAT Phathom Pharmaceuticals, Inc.
9.48
-3.27%
IMCR Immunocore Holdings plc
54.74
+0.29%
KYMR Kymera Therapeutics, Inc.
35.12
+4.03%
MLTX MoonLake Immunotherapeutics
42.25
-2.90%
ASND Ascendis Pharma A/S
140.89
-0.90%